Amir Hossein Barjasteh

Dr. Amir Hossein Barjasteh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
AZAmir Sadra Zangouei
Amir Sadra Zangouei
ABAmir Hossein Barjasteh
Amir Hossein Barjasteh
HRHamid Reza Rahimi
Hamid Reza Rahimi
MMmajid mojarrad
majid mojarrad
MMMeysam Moghbeli
Meysam Moghbeli
Background: Bladder cancer (BCa) is a frequent urothelial malignancy with a high ratio of morbidity and mortality. Various genetic and environmental factors are involved in BCa progression. Since, majority of BCa cases are diagnosed after macroscopic clinical symptoms, it is required to find efficient markers for the early detection. Receptor tyrosine-kinases (RTKs) and non-receptor tyrosine-kinases (nRTKs) have pivotal roles in various cellular processes such as growth, migration, differentiation, and metabolism through different signaling pathways. Tyrosine-kinase deregulations are observed during tumor progressions via mutations, amplification, and chromosomal abnormalities which introduces these factors as important candidates of anti-cancer therapies.Main body: For the first time in present review we have summarized all of the reported tyrosine-kinases which have been significantly associated with the clinicopathological features of BCa patients.Conclusions: This review highlights the importance of tyrosine-kinases as critical markers in early detection and therapeutic purposes among BCa patients and clarifies the molecular biology of tyrosine-kinases during BCa progression and metastasis.

19 February 2026 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MKMohammad Reza Keivany
Mohammad Reza Keivany
EAElham Shojae Asrami
Elham Shojae Asrami
MBMohammadreza Besharatloo
Mohammadreza Besharatloo
HLHanieh Latifi
Hanieh Latifi
ABAmir Hossein Barjasteh
Amir Hossein Barjasteh
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have transformed outcomes fo